Method for detecting presence of target nucleic acid in sample
Through a single-channel electrophysiological detection system and MscS emiocole, the problems of complexity and cost of nucleic acid detection in the prior art are solved, and fast, convenient and high specific nucleic acid detection is achieved, which is suitable for clinical applications.
Patent Information
- Application Number
- CN202411186663.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-08-30
- Filing Date
- 2022-06-29
- Publication Date
- 2024-11-22
AI Technical Summary
The existing nanopore-based nucleic acid detection methods are complex and costly, unable to meet the needs of fast and convenient clinical applications, and require auxiliary polynucleotide binding proteins and chemical modifications.
Using a single-channel electrophysiological detection system, the presence of target nucleic acid in the sample is detected by the MscS variant Emmetope, and the interaction between the nucleic acid amplification product and the transmembrane pores is generated to quantify the remaining nucleotides to determine the target nucleic acid. exist.
It realizes fast, low-cost, easy to detect high throughput, has better specificity and sensitivity, and can convert mechanical stimulation into electrical signals in milliseconds. It is suitable for directly detecting different nucleotides without being disturbed by other substances. .
Smart Images

Figure CN118996004A_ABST
Abstract
Description
[0001] This application is a divisional application of a Chinese invention patent application with the application number 202210758428.7, the application date of June 29, 2022, and the invention title "A Method for Detecting the Presence of Target Nucleic Acid in a Test Sample".
[0002] This application claims the priority of the Chinese invention patent application [CN2021110062606] titled "Bio-nanopore System Based on PaMscS for dNTPs and COVID-19 Detection" filed on August 30, 2021, and the Chinese invention patent application [CN2021110042496] titled "Bio-nanopore System Based on PaMscS for Small Molecule Drug Detection and Whole Blood Detection" filed on August 30, 2021. The two priority invention patent applications are incorporated herein by reference in their entireties. Technical Field
[0003] The present invention belongs to the field of nanopore detection, and particularly relates to a method for detecting the presence of target nucleic acid in a test sample. Background Art
[0004] Transmembrane pores (such as nanopores) as sensors have shown great potential in the field of nucleic acid detection. When a molecule passes through the channel inside the nanopore, specific blocking currents and translocation events occur. Based on the blocking current and translocation frequency of the molecule, qualitative and / or quantitative analysis of the target molecule can be achieved. Some protein nanopores with appropriate channel pore diameters have been used in applications of nanobiotechnology, such as α-hemolysin (α-HL), MspA, CsgG, Aerolysin, phi29 connector, etc. These protein nanopores mainly come from bacterial porins or virus families, and have pore diameters (1.0 nm - 3.6 nm) approximately the size of single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA). Therefore, they are suitable for detecting nucleic acids and have been used in DNA / RNA sequencing, nucleic acid biomarker detection, and biomolecular interaction research.
[0005] However, the current detection idea based on nanopore is to make a single polynucleotide (DNA / RNA) pass through the hole and directly identify the nucleotide. Therefore, polynucleotide binding proteins (such as helicases, polymerases) are often needed to act as molecular brakes for polynucleotides to pass through nanopores. For example, CN106459159B discloses a method for characterizing a target polynucleotide using nanopores. The method requires the participation of an auxiliary "molecular brake", that is, it is necessary to contact the polynucleotide with the constructed nanopore and polynucleotide binding protein so that the polynucleotide moves through the nanopore and this movement is controlled by the polynucleotide binding protein. CN110168104A discloses a method for characterizing an analyte using nanopores. The method not only requires the participation of polynucleotide binding proteins, but also requires label modification of the nanopore and an adapter that can be attached to a double-stranded polynucleotide to increase the probability of passing the complementary chain. The sequencing system of the above method is complex and expensive, and it is impossible to meet the needs of rapid and convenient nucleic acid detection technology in application scenarios such as clinical. Summary of the invention
[0006] In view of this, the present invention provides a method for detecting the presence of a target nucleic acid in a sample, and the specific technical solution is as follows.
[0007] A method for detecting the presence of a target nucleic acid in a sample, comprising the following steps: S1: placing the sample in a nucleic acid amplification system and performing nucleic acid amplification, determining the number of substrate nucleotides in the nucleic acid amplification system, and obtaining a nucleic acid amplification product of the sample; S2: adding the nucleic acid amplification product of the sample to a single-channel electrophysiological detection system, wherein the single-channel electrophysiological detection system comprises: a transmembrane pore, an insulating membrane, a first medium, and a second medium, wherein the transmembrane pore is embedded in the insulating membrane, the insulating membrane separates the first medium from the second medium, the transmembrane pore provides a channel connecting the first medium and the second medium, and the nucleic acid amplification product of the sample is added to the first medium; S3 applies a driving force between the first medium and the second medium, so that the remaining nucleotides in the nucleic acid amplification product of the sample interact with the transmembrane pore and generate an electrical signal; S4 quantifies the electrical signal to obtain the number of the remaining nucleotides; S5 compares the number of the remaining nucleotides with the number of the substrate nucleotides to determine whether the target nucleic acid exists in the sample.
[0008] Furthermore, the transmembrane pore is a MscS variant angstrom pore.
[0009] Furthermore, the MscS variants include side pore volume variants and / or side pore charge variants.
[0010] Furthermore, the charge properties and / or pore size of the opening of the angstrom pore of the MscS variant are adjustable.
[0011] Furthermore, the opening is adjusted in a manner including subjecting the insulating film to mechanical force stimulation and / or changing the physical state of the insulating film.
[0012] Furthermore, the mechanical force stimulation includes one or more of a change in the osmotic pressure difference of the medium on both sides of the insulating membrane, direct physical stimulation of the insulating membrane by a microneedle, and stimulation of the insulating membrane by negative air pressure.
[0013] Furthermore, the aperture of the opening can be adjusted according to the following methods: (1) Selection of the types of the first medium and the second medium; and / or (2) The osmotic pressure difference between the first medium and the second medium.
[0014] Furthermore, the osmotic pressure difference between the first medium and the second medium is adjusted by the concentration difference between the first medium and the second medium.
[0015] Further, the concentration difference between the first medium and the second medium is about 0-270 mM.
[0016] Furthermore, the first medium and / or the second medium includes one or more of a sodium chloride solution, a lithium chloride solution, a cesium chloride solution, a potassium chloride solution and a sodium bromide solution.
[0017] Furthermore, the MscS variant EMI150 is derived from Bacillus.
[0018] Furthermore, the MscS variant angstrom includes one or more of Pseudomonas aeruginosa, Escherichia coli, Tengchong thermophilic anaerobic bacteria and Helicobacter pylori.
[0019] Furthermore, the MscS variant angstrom pore is a PaMscS variant angstrom pore.
[0020] Further, the PaMscS variant angstrom pores include 130A, 130H, 180R, 271I, 130S and 130P One or more of .
[0021] Furthermore, the nucleic acid amplification is performed by one or more of polymerase chain reaction, ligase chain reaction, strand displacement amplification technology, transcription-mediated amplification technology, and loop-mediated isothermal amplification technology.
[0022] Furthermore, the nucleotides include ribonucleotides and / or deoxyribonucleotides.
[0023] Furthermore, the nucleotides include one or more of dGTP, dATP, dTTP, dCTP, dUTP, GTP, ATP, TTP, CTP, and UTP.
[0024] Furthermore, the nucleic acid amplification system further comprises: (1) a probe, wherein the probe comprises a complementary region and a repeat region, wherein the complementary region comprises a sequence complementary to the target nucleic acid, and the repeat region comprises an oligonucleotide sequence repeating the same base, wherein the base comprises A, T, C, G, or U; or (2) Primers specific for the target nucleic acid.
[0025] Furthermore, the target nucleic acid is coronavirus nucleic acid.
[0026] Furthermore, the coronavirus includes one or more of SARS-CoV-2, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV and MERS-CoV.
[0027] Furthermore, the insulating film includes a phospholipid membrane and / or a polymer membrane.
[0028] On the other hand, the present invention also provides a virus rapid detection kit, comprising: (1) MscS angstrom pore; (2) Insulating film; (3) Conductivity fluid; (4) Primers or probes specific for the nucleic acid of the virus.
[0029] Further, the MscS angstrom pore comprises side pore volume variants and / or side pore charge variants of MscS.
[0030] Furthermore, the insulating film includes a phospholipid membrane and / or a polymer membrane.
[0031] Furthermore, the conductive liquid includes one or more of a sodium chloride solution, a lithium chloride solution, a cesium chloride solution, a potassium chloride solution and a sodium bromide solution.
[0032] Furthermore, the angstrom pore is a PaMscS variant angstrom pore.
[0033] Further, the angstrom pores include one or more of 130A, 130H, 180R, 271I, 130S and 130P.
[0034] Compared with the prior art, the present invention has the following beneficial effects:
[0035] The present invention provides a method for detecting the presence of a target nucleic acid in a sample using a single-channel electrophysiological detection system.
[0036] 1) The method provided by the present invention can quickly detect the presence of target nucleic acids in samples. Traditional nucleic acid detection methods usually require fluorescent labeling or staining of target nucleic acids, and therefore rely on expensive fluorescence monitoring equipment or staining systems. Current nanopore-based nucleic acid detection methods often require complex systems such as auxiliary polynucleotide binding proteins (such as helicases, polymerases). The method provided by the present invention utilizes transmembrane pores and only needs to detect the consumption of substrate dNTPs in an in vitro nucleic acid amplification system (such as substrate dNTPs, polymerases, and reverse transcriptases) to determine whether the target nucleic acid exists in the nucleic acid amplification system. It has the advantages of being fast, low cost, easy for high-throughput detection, and having good specificity and sensitivity. The transmembrane pores involved in the present invention can detect (or distinguish) different nucleotides and are not interfered with by other substances in the nucleic acid amplification system (such as amplified nucleic acids and enzymes).
[0037] 2) Preferably, the transmembrane pore of the present invention is a MscS (small conductance mechanosensitive channel) angstrom pore, which has a narrow pore size and an adjustable pore size (which can also be understood as a flexible structure). It is estimated that the pore size range of the MscS angstrom pore is ~6-16 angstroms, which is much smaller than the nanopores commonly used in the prior art (for example, the pore size of the α-hemolysin nanopore is about 1.4-2.4nm, i.e. 14-24 angstroms). The MscS angstrom pore can convert mechanical stimulation into electrical or biochemical signals within milliseconds, thereby inducing the regulation of the channel configuration. By utilizing the sensitivity of the MscS angstrom pore to the mechanical force stimulation and / or the change in the physical state of the insulating membrane, the pore size of the MscS angstrom pore can be adjusted by affecting the insulating membrane without complicated chemical modification. For example, the concentrations of the first medium and the second medium (i.e., 30mM NaCl / 300mM NaCl, 100mM NaCl / 300mMNaCl, and 300mMNaCl / 300mM NaCl) can be adjusted to adjust the osmotic pressure difference on both sides of the insulating membrane and thus adjust the pore size, thereby optimizing the selectivity for dNTPs and improving the discrimination of dNTPs. The protein nanopores in the prior art usually have a fixed channel structure, and the direct detection of nucleotides (e.g., dNTPs and similar molecules) usually requires additional protein engineering modification or chemical modification. The pore size of the MscS angstrom pore involved in the present invention can be reversibly adjusted in situ by simply changing the external conditions, and is suitable for direct single-molecule sensing and recognition of nucleotides (which can also be understood as direct detection of nucleotides).
[0038] As used herein, the term "derived from" refers not only to proteins produced by the strain of the organism in question, but also to proteins encoded by a DNA sequence isolated from such strain and produced in a host organism containing such DNA sequence. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the prior art descriptions. Obviously, the drawings described below are some embodiments of the present invention, and for ordinary technicians in this field, other drawings can be obtained based on these drawings without creative labor.
[0040] Figure 1 Electrophysiological testing based on PaMscS angstrom pores is shown;
[0041] Figure 2 SARS-CoV-2 nucleic acid detection based on real-time monitoring of dNTPs consumption by PaMscS2 is shown;
[0042] Figure 3 PaMscS proteins (including: 1: wild-type PaMscS; 2: W130A mutant; 3: K180R mutant; 4: marker) SDS-PAGE results;
[0043] Figure 4 The electrical signal information of the PaMscS angstrom pore is shown;
[0044] Figure 5 shows the current trace through a single PaMscS1 angstrom pore under a ramp voltage from 0 mV to +100 mV;
[0045] Figure 6 The transport capacity of different ions through the PaMscS1 pore is shown (buffer conditions: 300 mM NaCl on the -cis side, 30 mM NaCl on the -trans side, n ≥ 3 for each data point, mean ± SD);
[0046] Figure 7 The translocation frequency statistics of dNTPs through the PaMscS1 angstrom pore at different voltages are shown (n=3);
[0047] Figure 8 It was shown that single-stranded DNA cannot translocate through the PaMscS1 pore;
[0048] Fig. 9 The results of angstrom pore detection of SARS-CoV-2orf1ab gene by loop-mediated isothermal amplification (LAMP) are shown;
[0049] Fig.10 The transport frequency of dNTPs through the PaMscS1 pore under different osmotic pressure differences is shown;
[0050] Fig.11 Detection of AFP aptamer and miR21 by dNTPs consumption by PaMscS1 is shown;
[0051] Fig.12 The current trace and dwell time distribution of single nucleotide detection by PaMscS1 are shown;
[0052] Fig.13 The results of native PAGE electrophoresis of PCR reagents mixed with miR21 and AFP aptamers are shown;
[0053] Fig.14 dNTP detection based on wild-type PaMscS angstrom pore is shown;
[0054] Fig.15 A single channel embedded current trace of wild-type EcMscS is shown (voltage +100 mV, conductance 30 mM: 300 mM NaCl);
[0055] Fig.16 Channel scanning voltage (−100 mV to 100 mV) of wild-type EcMscS is shown;
[0056] Fig.17 The conductance distribution of wild-type EcMscS is shown;
[0057] Fig.18 Shown is a sequence alignment of PaMscS with MscS from other bacteria. DETAILED DESCRIPTION
[0058] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0059] It should be noted that, in this article, the terms "include", "comprises" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, an element defined by the sentence "comprises a ..." does not exclude the existence of other identical elements in the process, method, article or device including the element.
[0060] As used in this specification, the term "about" typically means + / - 5% of the stated value, more typically + / - 4% of the stated value, more typically + / - 3% of the stated value, more typically + / - 2% of the stated value, even more typically + / - 1% of the stated value, and even more typically + / - 0.5% of the stated value.
[0061] In this specification, some embodiments may be disclosed in a format that is within a certain range. The description of "in a certain range" is only for convenience and brevity, and should not be interpreted as a rigid limitation of the disclosed range. Therefore, the description of a range should be considered to have specifically disclosed all possible sub-ranges and independent numerical values within this range. For example, the description of a range of 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as individual numbers within this range, such as 1, 2, 3, 4, 5 and 6. The above rules apply regardless of the breadth of the range.
[0062] Detailed description of the drawings
[0063] Figure 1 : A. Schematic diagram of the electrophysiological measurement chamber. B. Single-hole insertion of PaMscS1 and PaMscS2 angstrom pores at +50 mv. C. IV relationship of PaMscS1 and PaMscS2 angstrom pores in the voltage range of -50 mv to +50 mv. D. Conductance distribution of PaMscS1 and PaMscS2 angstrom pores (N=18, respectively) (buffer conditions: -cis end: 300 mM NaCl, -trans end: 30 mM NaCl). E. Detection of dNTPs through PaMscS mutant angstrom pores (buffer conditions: -cis end: 300 mM NaCl, -trans end: 30 mM NaCl, and the voltage was +50 mv).
[0064] Figure 2:A. Schematic diagram of angstrom pore detection of SARS-CoV-2. B. Detection results of SARS-CoV-2 Orf1ab gene under gradient copy number (buffer conditions: -cis end: 300mM NaCl, -trans end: 100mM NaCl, voltage +50mV, negative control (NC) group: n=4, 10^11 copies / mL group: n=4, 10^8 copies / mL group: n=4, 10^5 copies / mL group: n=4, 10^3 copies / mL group: n=3). C. Test results of 22 clinical samples, including 15 positive samples (patient numbers: 1-15) and 7 negative samples (patient numbers: 16-22), the results of 21 samples by angstrom were consistent with the results of hospital qPCR test (patient numbers: 1-15, 17-22), and 1 negative sample (patient number: 16) was diagnosed as positive by angstrom (buffer conditions: -cis end: 300mMNaCl, -trans end: 100mM NaCl, voltage of +50mV). D. Monitoring the consumption of dNTPs by MscS angstrom can be combined with nucleic acid amplification techniques (NAAT), such as polymerase chain reaction (PCR) and chain displacement amplification (SDA).
[0065] Figure 4 :A. Background signal frequency of wild-type PaMscS and mutant PaMscS1 and PaMscS2. The background noise frequency of PaMscS1 and PaMscS2 is lower than that of wild-type PaMscS (voltage is +50mv, n≥3). B. Time of insertion of PaMscS1 and PaMscS2 angstrom pore. PaMscS2 angstrom pore has higher membrane fusion efficiency than PaMscS1 (n≥3). C. Distribution of dNTPs blocking current in the angstrom pores of PaMscS1 and PaMscS2.
[0066] Figure 5 : Voltage gating was observed when the voltage was raised above +90 mV (buffer conditions: -cis end: 300 mM NaCl, -trans end: 30 mM NaCl, sampling frequency: 4999 Hz).
[0067] Figure 8 : Voltage: +50 mV; Buffer conditions: 300 mM NaCl on the cis side, 30 mM NaCl on the trans side. The final concentration of ssDNA was 5 μM, and the sequence was 5′TAGCTTATCAGACTGATGTTGA 3′ (SEQ ID NO: 5).
[0068] Fig. 9 : Samples containing 10^3 copies / mL to 10^11 copies / mL of the Orf1ab gene can be tested.
[0069] Fig.10 : The translocation frequencies of dCTP (in orange) and dGTP (in blue) were tested under different osmotic pressure differences, symmetric (A, 300 mM NaCl: 300 mM NaCl for cis end: trans end), low osmotic pressure difference (LOD) (B, 300mM NaCl:100mM NaCl for cis end:trans end), and high osmotic pressure difference (HOD) (C, 300mM NaCl: 30mM NaCl was used for cis-end: trans-end). Four sets of dNTPs concentrations, 0.5mM, 1.0mM, 1.5mM, and 2.0mM, were used to test the translocation of dCTP and dGTP. D. Relationship between translocation frequency and dCTP / dGTP concentration under symmetric, low osmotic pressure difference, and high osmotic pressure difference conditions (n=3 for each data point). E. Under 3 different osmotic pressure difference conditions, f dCTP and f dGTP rate of increase.
[0070] Fig.11 :A. Schematic diagram of the detection strategy. B. Current traces of the no-target control group, miR21 group, AFP aptamer group, and group with both miR21 and AFP aptamer. C. Current distribution of the four detection groups. D. Relative increase of dATP and dGTP signals in the four groups. Samples without miR21 and AFP aptamer will not lead to dNTPs consumption; samples with miR21 will lead to more dATP consumption and relatively lower dATP translocation frequency; samples with AFP aptamer will lead to more dGTP consumption and relatively lower dGTP translocation frequency; samples with both miR21 and AFP aptamer will lead to more dATP and dGTP consumption and relatively lower dATP and dGTP translocation frequency (buffer conditions are -cis end: 300mMNaCl, -trans end: 100mM NaCl, voltage is +50mV, n=3 for each experiment).
[0071] Fig.12 : Dwell time distribution: dGTP (A), dATP (B), dTTP (C) and dCTP (D); the concentration of each nucleotide was 2 mM and the buffer conditions were -cis end: 300 mM NaCl, -trans end: 30 mM NaCl, and the voltage was +50 mV.
[0072] Fig.13: 1: DNA template 1 (containing poly T); 2: DNA template 2 (containing poly C); 3: PCR reagents with miR21 and AFP adaptors; 4: control group (without miR21 and AFP adaptors).
[0073] Transmembrane pore
[0074] A transmembrane pore is a structure that passes through the membrane to some extent. It allows an analyte to flow through or into the membrane, driven by an applied driving force. A transmembrane pore usually passes through the entire membrane, allowing the analyte to flow from one side of the membrane to the other side of the membrane. However, a transmembrane pore does not necessarily have to pass through the membrane. One end of it can be closed. For example, the pore can be a well, gap, channel, groove or slit in the membrane, along which the analyte can flow or flow into it. Any transmembrane pore can be used in the present invention. The transmembrane pore can be biological or artificial. Suitable pores can be protein pores, polynucleotide pores and solid-state pores.
[0075] In the present invention, the transmembrane pore should at least have the ability to detect and distinguish multiple nucleotides, and is preferably a transmembrane protein pore. In other words, the transmembrane protein pore of the present invention can allow the analyte driven by a driving force to flow from one side of the membrane to the other side.
[0076] In a specific embodiment of the present invention, the transmembrane pore used in the present invention is a small conductance mechanosensitive channel (Mechanosensitive channel of small conductance, MscS), preferably PaMscS (Pseudomonas aeruginosa small conductance mechanosensitive channel) or its variant. The variant (also understood as a "mutant") can be a naturally occurring variant expressed by an organism (such as Pseudomonas aeruginosa). Variants also include non-naturally occurring variants produced by recombinant technology. In the present invention, "PaMscS variant", "mutant PaMscS", "mutant PaMscS", "PaMscS mutant" means the same unless otherwise indicated.
[0077] In one embodiment of the present invention, the transmembrane pore may be an MscS variant. Amino acid substitutions may be made to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO: 3 or SEQ ID NO: 4, for example, single or multiple amino acid substitutions. The substitutions may be conservative substitutions or non-conservative substitutions. Preferably, non-conservative substitutions may be made to one or more positions of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO: 3 or SEQ ID NO: 4, wherein the substituted amino acid residue is replaced by an amino acid with significantly different chemical properties and / or physical size. Further, the MscS variants can be divided into side pore volume variants and side pore charge variants. Side pore volume variants refer to variants in which the mutation site is located at the side opening of the cytoplasmic end (which can also be understood as a "side pore") and the side pore volume is changed by changing the amino acid at the site. Side pore charge variants refer to variants in which the mutation site is located at the side opening of the cytoplasmic end and the side pore charge is changed by changing the amino acid at the site. For example, the side pore volume variant may be a replacement of a larger volume amino acid (e.g., tryptophan (W)) with a smaller volume amino acid (e.g., alanine (A), serine (S) or proline (P)), or vice versa. Side pore charge variants may be a replacement of an amino acid with a certain charge with an oppositely charged or neutral amino acid, or a replacement of a neutral amino acid with a charged amino acid. In general, non-limiting examples of positively charged amino acids include histidine, arginine and lysine; non-limiting examples of negatively charged amino acids include aspartic acid and glutamic acid; non-limiting examples of neutral amino acids include glycine, alanine, phenylalanine, valine, leucine, isoleucine, cysteine, asparagine, glutamine, serine, threonine, tyrosine, methionine, proline and tryptophan. Conservative or non-conservative substitutions of amino acids, as well as many different types of modifications (deletion, substitution, addition) of amino acids are well known in the art, and those skilled in the art can modify MscS according to actual conditions to obtain corresponding MscS variants. The means of modification include modifying the corresponding DNA sequence (for example, directly synthesizing the corresponding protein after modifying the DNA sequence information or performing site-directed mutation on the DNA sequence using PCR), thereby obtaining the corresponding variant (and its corresponding DNA sequence).
[0078] In a specific embodiment, the MscS variant may be a PaMscS variant. The PaMscS variant, for example, includes one or more of 130A, 130H, 180R, 271I, 130S and 130P. The side pore volume mutants of PaMscS, for example, include 130A, 130S, 130P, and the side pore charge variants of PaMscS, for example, include 130H, 180R, 271I. Such modification can change the pore size of the modified side pore (also understood as "pore size"), thereby improving the detection ability of analytes of specific molecular volume; it can also change the local charge characteristics of the modified side pore channel, thereby improving the detection ability of specific charged analytes; it can also enhance the stability of the protein channel current of the PaMscS variant.
[0079] In one embodiment of the present invention, the transmembrane pore may be wild-type PaMscS, which has a high background noise. But it still has the ability to detect the analyte.
[0080] In one embodiment of the present invention, the transmembrane pore may be a wild-type EcMscS (small conductance mechanosensitive channel of Escherichia coli) or a variant thereof. The structures of EcMscS and PaMscS are highly similar, and they can also form a stable channel current and have the ability to detect analytes. The sequence similarity between PaMscS and EcMscS is 60%. Conservative or non-conservative substitutions of amino acids, as well as many different types of modifications (deletion, substitution, addition) of amino acids are well known in the art, and those skilled in the art can modify EcMscS according to actual conditions to obtain corresponding EcMscS variants.
[0081] In another embodiment of the present invention, in addition to Escherichia coli and Pseudomonas aeruginosa, the MscS can also be derived from other bacilli, such as Thermoanaerobacter tengcongensis and Helicobacter pylori. The structures of PaMscS, TtMscS and HpMscS are also highly similar, and the sequence similarities are 55% and 44%, respectively. Combining the actual electrophysiological detection results of PaMscS and EcMscS, it can be seen that the reason why MscS can be used as a transmembrane pore to detect analytes is that it has a highly similar structure and similar functions. Conservative substitution or non-conservative substitution of amino acids, as well as many different types of modifications (deletion, substitution, addition) of amino acids are well known in the art, and those skilled in the art can modify MscS according to actual conditions to obtain corresponding MscS variants.
[0082] Analytes
[0083] The analyte is a charged substance. If the analyte has a net charge, it is charged. The analyte can be negatively charged or positively charged. If the analyte has a net negative charge, it is negatively charged. If the analyte has a net positive charge, it is positively charged. Suitable analytes should be substances with a size less than or equal to the pore size of the transmembrane pore, preferably nucleotides, amino acids, peptides, drug molecules.
[0084] In one embodiment of the present invention, the analyte can be a nucleotide. "Nucleotide" refers to a monomeric unit consisting of a heterocyclic base, a sugar and a phosphate group. It should be understood that the heterocyclic base includes naturally occurring bases (guanine (G), adenine (A), cytosine (C), thymine (T) and uracil (U)) and non-natural base analogs. Sugar includes naturally occurring sugars (deoxyribose and ribose) and non-natural sugar analogs. The nucleotide includes deoxyribonucleotides and ribonucleotides, such as ATP, dATP, CTP, dCTP, GTP, dGTP, UTP, TTP, dUTP, GMP, UMP, TMP, CMP, dGMP, dAMP, dTMP, dCMP, dUMP, ADP, GDP, TDP, UDP, CDP, dADP, dGDP, dTDP, dUDP, dCDP. The nucleotide includes naturally occurring nucleotides and non-natural nucleotide analogs that hybridize with nucleic acids in a manner similar to naturally occurring nucleotides. The nucleotide is free (or can be understood as "single"). Preferably, the nucleotide is ATP, dATP, CTP, dCTP, GTP, dGTP, UTP, TTP, dUTP.
[0085] Single channel electrophysiological detection system
[0086] "Single-channel electrophysiological detection system" refers to a system capable of detecting changes in electrophysiological properties (e.g., current) of a single channel under the influence of an analyte, which includes a transmembrane pore, an insulating membrane, a first medium, and a second medium. In one embodiment of the present invention, the transmembrane pore is a pore with an angstrom size (referred to as "angstrom pore"), specifically a small conductance mechanosensitive channel (MscS) angstrom pore. The pore with an angstrom size is preferably a heptamer structure with radial symmetry and a cylindrical shape, and the heptamer structure includes 7 side openings and 1 bottom opening. In one embodiment of the present invention, the pore with an angstrom size has a typical heptamer structure with radial symmetry and a cylindrical shape, and the heptamer structure includes 8 openings, of which 7 equal openings are distributed on the side, and the 8th opening is distributed on the bottom and is formed by 7 subunits; the pore sizes of the above 8 openings can be adjusted. The pore with an angstrom size allows the analyte to translocate from one side of the insulating membrane to the other side.
[0087] In one embodiment of the present invention, the pores with angstrom size are embedded in the insulating film, and the insulating film (which can also be understood as a complex of the pores with angstrom size and the insulating film) separates the first medium from the second medium, and the pores with angstrom size provide a channel connecting the first medium and the second medium; after applying a driving force between the first medium and the second medium, the analyte located in the first medium interacts with the MscS angstrom pore to form a current (i.e., an electrical signal). In the present invention, the "first medium" refers to the medium where the analyte is located when it is added to the single-channel electrophysiological detection system; the "second medium" refers to the other side of the "first medium" in the two parts of the medium separated by the insulating film. In the present invention, the driving force refers to the force that drives the analyte to interact with the transmembrane pore by means of electric potential, electroosmotic flow, concentration gradient, etc.
[0088] The first medium and the second medium may be the same or different, and the first medium and the second medium may include a conductive liquid. The conductive liquid is an aqueous solution of an alkali metal halide, specifically sodium chloride (NaCl), lithium chloride (LiCl), cesium chloride (CsCl), potassium chloride (KCl), sodium bromide (NaCl). In one embodiment of the present invention, the concentrations of the conductive liquid contained in the first medium and the second medium are different. In other words, there is a difference in the concentration of the conductive liquid in the first medium and the second medium, which results in a difference in the osmotic pressure on both sides of the insulating membrane. The first medium and / or Or the second medium may further include a buffer, such as HEPES. The concentration of the first medium and / or the second medium may range from 30 mM to 3M.
[0089] The insulating membrane refers to a membrane having the ability to carry transmembrane pores (or nanopores) and block the ionic current passing through non-transmembrane pores (or nanopores). The insulating membrane may include a phospholipid membrane and / or a polymer membrane. Exemplary phospholipid membranes include DPHPC, DOPC, and E. coli lipid, and exemplary polymer membranes include triblock copolymer polymer membranes.
[0090] The single-channel electrophysiological detection system of the present invention may include any small conductance mechanical force sensitive channel described herein, such as wild-type PaMscS (SEQ ID NO: 1), wild-type EcMscS (SEQ ID NO: 2), wild-type TtMscS (SEQ ID NO: 3) and wild-type HpMscS (SEQ ID NO: 4) and their corresponding variants, and the specific sequence information of the above four MscS is shown in Table 4. For example, the small conductance mechanical force sensitive channel may be mutant PaMscS1 (W130A), mutant PaMscS2 (K180R), mutant PaMscS3 (V271I) (which has the ability to detect small molecule drugs, experimental data not shown).
[0091] Table 4: Amino acid sequence information of four MscS
[0092] In a specific embodiment of the present invention, the single-channel electrophysiological detection system includes two electrolyte chambers, which are separated by an insulating membrane to form a trans compartment and a cis compartment, and the hole of the angstrom pore is embedded in the insulating membrane, and there is only a small-conductance mechanical force sensitive channel angstrom pore on the insulating membrane to connect the two electrolyte chambers. When an electric potential is applied to the two electrolyte chambers, the electrolyte ions in the solution in the electrolyte chamber move through electrophoresis and pass through the angstrom pore.
[0093] In one embodiment of the present invention, the small conductance mechanosensitive channel (MscS) angstrom pore can be embedded in an insulating membrane, but it retains the ability to change the protein structure in response to mechanical force stimulation of the insulating membrane and changes in the physical state of the insulating membrane. Specifically, mechanical force stimulation includes changes in osmotic pressure on both sides of the insulating membrane, direct physical stimulation of the insulating membrane by microneedles, stimulation of the insulating membrane by negative air pressure, etc. The physical changes of the insulating membrane include changes in the thickness of the insulating membrane, changes in the composition of the insulating membrane, and changes in the surface curvature of the insulating membrane. The change in protein structure includes changing the charge properties and / or pore size of the opening of MscS. Further, the charge properties and / or pore size of the opening changed by the MscS angstrom pore can be used to detect different analytes. The adjustable range of the pore size of the angstrom pore involved in the present invention can be 5-15 angstroms.
[0094] The interaction between the transmembrane pore and the analyte
[0095] The analyte may contact the transmembrane pore on either side of the insulating membrane. The analyte may contact either side of the insulating membrane so that the analyte passes through the channel of the transmembrane pore to reach the other side of the insulating membrane. In this case, the analyte interacts with the transmembrane pore when it passes through the insulating membrane via the channel of the pore. Alternatively, the analyte may contact the side of the insulating membrane, which may allow the analyte to interact with the transmembrane pore, separate from the transmembrane pore and remain on the same side of the insulating membrane. The analyte may interact with the transmembrane pore in any manner and at any site. The analyte may also hit the transmembrane pore, interact with the transmembrane pore, separate from the transmembrane pore and remain on the same side of the insulating membrane.
[0096] During the interaction between the analyte and the transmembrane pore, the analyte affects the current flowing through the transmembrane pore in a manner specific to the analyte, i.e., the current flowing through the transmembrane pore is characteristic for the specific analyte. A control experiment can be performed to determine the effect of a specific analyte on the current flowing through the transmembrane pore, and then to identify the specific analyte in the sample or to determine whether the specific analyte is present in the sample. More specifically, the current pattern obtained by detecting the analyte can be compared with a known current pattern obtained under the same conditions using a known analyte to identify the presence or absence of the analyte or the concentration, etc.
[0097] The single-channel electrophysiological detection system of the present invention may further include one or more measuring devices for measuring the current flowing through the transmembrane pore, such as a patch clamp amplifier or a data acquisition device.
[0098] sample
[0099] The analyte may be present in any suitable sample. The present invention is usually performed on a sample known to contain or suspected to contain the analyte. The present invention may be performed on a sample containing one or more analytes of unknown type. Alternatively, The present invention can confirm the identity of the one or more analytes known to be present or expected to be present in the sample.
[0100] The sample can be a biological sample. The present invention can be performed in vitro on a sample obtained from or extracted from any organism or microorganism. The present invention can also be performed in vitro on a sample obtained from or extracted from any virus. Preferably, the sample is a fluid sample. The sample generally includes body fluids. The sample can be a body fluid sample, such as urine, blood, serum, plasma, lymph, cyst fluid, pleural fluid, ascites fluid, peritoneal fluid, amniotic fluid, epididymal fluid, cerebrospinal fluid, bronchoalveolar lavage fluid, breast milk, tears, saliva, sputum or a combination thereof. The sample can be derived from humans or other mammals. The sample can be a non-biological sample. The non-biological sample is preferably a fluid sample, such as drinking water, sea water, river water and reagents for laboratory tests.
[0101] The sample may not be processed before analysis, for example, the analyte may be detected directly in whole blood. The sample may also be processed before analysis, for example, by centrifugation, filtration, dilution, precipitation or other physical or chemical means known in the art.
[0102] In one embodiment of the present invention, the sample is a nucleic acid amplification product.
[0103] Method for detecting the presence of nucleic acid in a sample
[0104] The present invention also provides a method for detecting the presence of nucleic acid in a sample. The method comprises: S1 placing the sample in a nucleic acid amplification system and performing nucleic acid amplification, determining the number of substrate nucleotides in the nucleic acid amplification system, and obtaining the nucleic acid amplification product of the sample; S2 adding the nucleic acid amplification product of the sample to a single-channel electrophysiological detection system, the single-channel electrophysiological detection system comprising: a transmembrane pore, an insulating membrane, a first medium, and a second medium, wherein the transmembrane pore is embedded in the insulating membrane, the insulating membrane separates the first medium from the second medium, the transmembrane pore provides a channel connecting the first medium and the second medium, and the nucleic acid amplification product of the sample is added to the first medium; S3 applying a driving force between the first medium and the second medium, the remaining nucleotides in the nucleic acid amplification product of the sample interact with the transmembrane pore and generate an electrical signal (current); S4 quantifying the electrical signal to obtain the number of the remaining nucleotides; S5 comparing the number of the remaining nucleotides with the number of the substrate nucleotides to determine whether the target nucleic acid in the sample exists. In some embodiments, S1 can be performed simultaneously with S2 or in the same system. Before detection, a threshold value can also be set. For example, when the number of at least one type of the remaining nucleotides is lower than the threshold value, the target nucleic acid is considered to be present in the sample; or, when the number of all types of remaining nucleotides is higher than the threshold value, the target nucleic acid is considered not to be present in the sample.
[0105] "Nucleic acid" refers to a deoxyribonucleotide or ribonucleotide polymer in single-stranded or double-stranded form. "Nucleic acid amplification" of a target nucleic acid refers to the process of constructing a nucleic acid chain in vitro that is identical or complementary to at least a portion of the target nucleic acid sequence. The nucleic acid amplification process can only occur when the target nucleic acid is present in the sample. In the nucleic acid amplification process, enzymes (such as nucleic acid polymerases, transcriptases) are usually used to produce multiple copies of the target nucleic acid or its fragments, or multiple copies of a sequence complementary to the target nucleic acid or its fragments. After the nucleic acid amplification process occurs, the substrate nucleotides of the nucleic acid amplification system will decrease accordingly as the number of copies increases. For example, Figure 2 and 11 are examples of nucleic acid amplification.
[0106] The principle of the method of the present invention is based on in vitro nucleic acid amplification technology to consume substrate nucleotides in the nucleic acid amplification system. Therefore, common in vitro nucleic acid amplification technologies, such as polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification technology (SDA), transcription-mediated amplification technology (TMA), and loop-mediated isothermal amplification technology (LAMP) can be used in conjunction with the method provided by the present invention.
[0107] In a specific embodiment, the method provided by the present invention can detect whether the new coronavirus nucleic acid is present in a sample.
[0108] In a specific embodiment, the method provided by the present invention can detect whether single-stranded nucleic acid exists in a sample.
[0109] In one embodiment of the present invention, the present invention constructs suitable primers (e.g., specific primers for SARS-CoV-2 nucleic acid) and introduces the primers into a nucleic acid amplification system (including substrate dNTPs, polymerase, reverse transcriptase). If the novel coronavirus nucleic acid is present in the sample, the novel coronavirus nucleic acid is amplified under appropriate conditions, consuming the substrate dNTPs and generating multiple copies of the nucleic acid. After the nucleic acid amplification product of the sample is added to the single-channel electrophysiological detection system provided by the present invention, the macromolecular substances (e.g., enzymes, polynucleotides, etc.) in the nucleic acid amplification system are difficult to pass through the transmembrane pore, that is, only free mononucleotides in the nucleic acid amplification system can pass through the transmembrane pore and generate a specific current, thereby determining the number of remaining nucleotides to determine whether the target novel coronavirus nucleic acid is present in the sample (i.e., if there is no target novel coronavirus nucleic acid in the sample, the number of remaining nucleotides is closer to the number of substrate nucleotides before nucleic acid amplification; if there is novel coronavirus nucleic acid in the sample, the number of remaining nucleotides is significantly lower than the number of substrate nucleotides before nucleic acid amplification, and more specifically, at least one nucleotide in the substrate nucleotide may be completely consumed).
[0110] In one embodiment of the present invention, the present invention constructs a suitable probe (for example, the probe includes a sequence complementary to the target nucleic acid sequence and a polynucleotide sequence) and introduces the probe into a nucleic acid amplification system (including substrate dNTPs and polymerase). If the target nucleic acid sequence exists in the sample, the target nucleic acid sequence is amplified under suitable conditions to consume substrate dNTPs and generate multiple copies of the target nucleic acid sequence; more specifically, since the probe also has a polynucleotide sequence (for example, Poly T, PolyA, Poly C, Poly G), after the target nucleic acid sequence binds to the probe, a large amount of substrate nucleotides corresponding to the polynucleotide sequence will be consumed. Therefore, it is possible to judge whether the target nucleic acid sequence exists in the sample based on the specific consumption of a certain substrate nucleotide. After the nucleic acid amplification product of the sample is added to the single-channel electrophysiological detection system provided by the present invention, it is difficult for the macromolecular substances (e.g., enzymes, polynucleotides, etc.) in the nucleic acid amplification system to pass through the transmembrane pore, that is, only free single nucleotides in the nucleic acid amplification system can pass through the transmembrane pore and generate specific current, thereby determining the number of remaining nucleotides to determine whether there is a target nucleic acid sequence in the sample (i.e., if there is no target nucleic acid sequence in the sample, the number of remaining nucleotides is closer to the number of substrate nucleotides before nucleic acid amplification; if there is a target nucleic acid sequence in the sample, the number of remaining nucleotides is significantly lower than the number of substrate nucleotides before nucleic acid amplification and the corresponding polynucleotides in the probe are consumed in large quantities. Based on this, different probes can be designed to simultaneously detect different target nucleic acid sequences in the same nucleic acid amplification system.
[0111] Specific implementation examples:
[0112] Embodiment 1
[0113] Materials and Methods
[0114] Sodium chloride (NaCl, >99.0%, CAS#7647-14-5), dNTP mixture (>99.0%), dATP (>97%, CAS#1927-31-7), dCTP (>98%, CAS#102783-51-7), dGTP (>98%, CAS#93919-41-6), dTTP (>98%, CAS#18423-43-3) was purchased from Sangon Biotech. Yeast extract (CAS#8013-01-2), trypsin (CAS#73049-73-7), ampicillin sodium salt (≥98.5%, CAS#69-52-3), Tris (≥99.9%, CAS#77-86-1), imidazole (≥99%, CAS#288-32-4), dodecyl-β-D-maltopyranoside (DDM) (≥99%, CAS#69227-93-6), isopropyl-β-D-thiogalactoside (IPTG) (≥99%, CAS#367-93-1), phenylmethylsulfonyl fluoride (Phenylmethylsulfonyl fluoride) (≥99%, CAS#367-93-1), and 1,1-d-d-maltopyranoside (DDM) (≥99%, CAS#69227-93-6). Fluoride, PMSF) (≥99.%, CAS#329-98-6), 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) (>99.5%, CAS#7365-45-9) were purchased from Sigma-Aldrich. Escherichia coli extracted phospholipids were purchased from Avanti. PrimeSTAR HSDNA polymerase was purchased from TaKaRa.
[0115] Expression and purification of wild-type and mutant PaMscS:
[0116] The PaMscS gene from Pseudomonas aeruginosa genomic DNA was amplified by polymerase chain reaction (PCR) using gene-specific primers and inserted into a plasmid using ClonExpress II One Step Cloning Kit (Vazyme). E. coli BL21 (DE3) cells containing the plasmid of the PaMscS gene were cultured in Luria-Bertani (LB) medium in the presence of 50 μg / mL ampicillin at 37°C and the protein was expressed and purified. The peak value was determined by SDS-PAGE analysis. It is particularly noted that the expression and purification steps of the wild-type and mutant proteins in the present invention are the same, except that there are differences in the plasmid synthesis stage due to the sequence differences between the wild-type protein and the mutant protein.
[0117] The experimental team of the present invention revealed the structure of the protein angstrom pore through modeling, which is a typical heptamer with radial symmetry and cylinder-like shape. It contains 8 openings, 7 on the side and 1 at the bottom. The N-terminal residues 1-13 are too flexible to be resolved in the model. In terms of topological structure, PaMscS can be divided into 2 parts, the transmembrane region and the large cytoplasmic part. Each monomer produces three N-terminal transmembrane helices, including TM1 (residues 17-52), TM2 (residues 58-83), and TM3 (residues 90-122). The C-terminal cytoplasmic region can be divided into a middle β domain and a COOH-terminal domain. TM1 and TM2 in each subunit are arranged together in an antiparallel orientation, with TM1 passing through the bilayer membrane on the outside of the channel and TM2 forming the central layer, thus forming a permeation path around the channel axis. The TM3 helix can be described as two helical segments, TM3a and TM3b, separated by a distinct kink of ∼53° at Gly108, which is a conserved residue in homology. TM3a, like TM1, passes through the membrane with a different deflection, while TM3b returns to the cytoplasm and interacts with the cytoplasmic region. In addition, the seven subunits form a The central pore senses tension and is associated with conformational changes. Comparing the MscS structures of Pseudomonas aeruginosa and Escherichia coli, the tilt angles of TM1 and TM2 of the former are smaller than those of the latter, which leads to a large deflection of the TM region, especially the loop between TM1 and TM2. In the cytoplasmic region, the middle β domain (residues 123-172) contains 5 β chains, which are tightly connected to the β chains of other different subunits. And the C-terminal domain (residues 177-273) is composed of 5 β chains and 2 α helices, which is a mixed structure. Between these two domains of adjacent monomers, there are 7 equal openings on the side, which are clearly visible, with a radius of about It is proposed to be responsible for ion permeation in EcMscS. In addition to these portals, an eighth opening exists at the base of the protein, represented by seven β-strands with a narrowest radius of In all sizes, extending to The PaMscS2 is parallel to the sevenfold axis and has a width in the perpendicular direction. The structure of PaMscS is similar to that of EcMscS in the closed state (PDB: 2OAU), and the TM domain has more than 101 rmsd. C α atoms, but in the open state (PDB: 2VV5), there is a large difference in the TM region, with an rmsd of These results suggest that the conformation of PaMscS in the structure reflects the closed state. The unique and delicate structure of the PaMscS angstrom pore shows great potential for detection.
[0118] Site mutation:
[0119] The DNA sequence corresponding to the corresponding amino acid site is modified (including direct synthesis or PCR mutation after DNA sequence modification), and the DNA sequence at the target mutation site is modified to the DNA sequence corresponding to the mutant protein. The mutant protein of the mutant PaMscS protein angstrom may include 130A, 130H, 180R, 271I, 130S or 130P.
[0120] Merging and single channel recording of membranes:
[0121] The experiments were performed in a vertical sample cell provided by Warner Instruments, and all current traces were recorded by a HEKAEPC 10USB patch clamp amplifier with a sampling frequency of 9900 Hz, unless otherwise mentioned. 1 μL of 25 mg / mL E. coli membrane was pre-coated on the 150 μm orifice of the cup, and then 1 mL of electrolyte solution (-trans end: 100 mM NaCl, 10 mM HEPES, pH 7.0; -cis end: 300 mM NaCl, 10 mM HEPES, pH 7.0) was added to both sides of the sample pool. Then about 2 / 3 of the electrolyte solution of the sample pool was sucked out from the -cis end with a 1 mL pipette. When the average current was close to 0 pA, the electrolyte solution was driven to the -cis side of the sample pool to form a planar phospholipid bilayer. After the phospholipid membrane was formed, the PaMscS1 protein solution was added to the -cis end. When PaMscS1 was embedded in the planar phospholipid bilayer, the current changed significantly. After the protein was embedded, 1 mL of solution was replaced and subsequent experiments were performed.
[0122] Single Nucleotide Detection:
[0123] Different groups of amplification products were detected by MscS angstrom pores. Different samples were added to the -cis end, and the current was recorded and observed at +50 mV for 20 minutes. When a stable PaMscS1 angstrom pore was formed on the planar phospholipid membrane, the single nucleotide to be detected was added to the -cis end of the sample pore, and then a voltage was applied and the current signal was recorded.
[0124] Collection and processing of coronavirus clinical samples
[0125] Clinical samples of SARS-CoV-2 patients were collected through throat swabs (patient numbers: 1-15) and blood (patient numbers: 16-22), and cDNA was obtained after reverse transcription.
[0126] RNA reverse transcription and PCR amplification
[0127] The SARS-CoV-2 RNA reverse transcription amplification system of the present invention is as follows: random hexamer (60 μM) and anchor polyT (23): 1 μL, dNTP mixture (each 10 mM): 1 μL, RNA sample: 11 μL. The reaction was carried out in a thermal cycler at 65°C. Incubate for 5 minutes. Immediately place the sample on ice for rapid cooling for more than 1 minute. Then, in a clean pre-PCR hood, mix the following reagents with the sample: 5X SuperScript IV buffer: 4 μL, DTT (100 mM): 1 μL, RNaseOUT RNase inhibitor: 1 μL, Superscript IV reverse transcriptase: 1 μL. Incubate the sample in a thermal cycler using a program of 42°C for 50 minutes and 70°C for 10 minutes to obtain cDNA. The cDNA PCR amplification system in the experiment of the present invention is as follows: ddH2O: 26.5μL, 5× PrimeSTAR buffer (Mg2+Plus): 10μL, dNTP mixture (2.5mM): 4μL, primer 1 (forward primer ORF P1, 10μM): 2μL, primer 2 (reverse primer ORF P2, 10μM): 2μL, PrimeSTAR HSDNA polymerase (2.5U / μL): 0.5μL, cDNA sample: 5μL. Amplification program is as follows: 95℃ Preheat for 5 minutes, heat denature at 98°C for 10 seconds. Anneal at 55°C for 15 seconds, then extend at 72°C for 12 seconds. Repeat the cycle 35 times in total. The above primers were synthesized independently by our research team, and the sequences are as follows: ORF P1 (SEQ ID NO:7): TTGTTTGAATAGTAGTTGTCTGA ORF P2 (SEQ ID NO:8): TCAACTCAATATGAGTATGGTACTG
[0128] Reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) and detection
[0129] Perform RT-LAMP reaction containing the following system: ddH2O: 4.1 μL, Colorimetric LAMP 2X Master Mix (DNA & RNA): 12.5μL, F3 (20μM): 0.2μL, B3 (20μM): 0.2μL, FIP (20μM): 1μL, BIP (20μM): 1μL, LoopF (20μM): 0.5μL, LoopB (20μM): 0.5μL, template: 5 μL. LAMP reaction was run at 60°C for 30 min.
[0130] Nucleic Acid Amplification and Detection:
[0131] The nucleic acid amplification system of the present invention is as follows: ddH2O: 64.6 μL, 5× PrimeSTAR buffer (Mg2+Plus): 20 μL, dNTP mixture (10 mM each): 6 μL, Primer 1 (miRNA21, 100 μM): 0.4 μL, Primer 2 (AFP aptamer, 10 μM): 4 μL, Template 1 (extraction, poly T): 2 μL, Template 2 (poly C, 1 μM): 2μL, PrimeSTAR HS DNA polymerase (2.5U / μL): 1μL. The amplification program is as follows: 95℃ preheating for 5min and 98℃ heat denaturation for 10s. 60℃ refractive annealing for 15s, then 68℃ extension for 23s. Repeat the cycle 30 times in total. The nucleic acid amplification results are as follows: Fig.13 shown.
[0132] Electrobiology data analysis
[0133] In the present invention, electrobiological data were processed by Clampfit software and plotted using Origin software.
[0134] Embodiment 2
[0135] Electrophysiological detection of PaMscS angstrom pores
[0136] The basic function of MscS is a fast on / off switch that responds to mechanical stimuli, such as changes in membrane tension during osmotic stress. The cytoplasmic domain of MscS functions as a molecular sieve that balances the loss of osmolytes during osmoadaptation. In the protein angstrom pore of the present invention, the seven side pores from the cytoplasmic region play a key role in the translocation of ions and solutes. Therefore, the side pore mutants PaMscS1(W130A) and PaMscS2 (K180R) was selected for subsequent studies due to its low background noise ( Figure 3 , Figure 4 AC). In electrophysiological experiments, the purified protein was added to the -cis end of the electrophysiological device ( Figure 1 A). When the PaMscS mutant channel was embedded in a bilayer lipid membrane (BLM, a type of insulating membrane), a stable channel current jump was observed at a voltage of +50 mV ( Figure 1 B). The channel conductance of PaMscS1 remains stable at voltages ranging from -50 mV to +50 mV ( Figure 1 C), and when the voltage is higher than +90 mV, the gating probability of PaMscS1 increases ( Figure 5 The conductance of the PaMscS1 angstrom pore is 0.64 ± 0.02 nS (n = 91, peak ± SD of Gaussian fitting, -cis end: 300 mM NaCl, -trans end: 30 mM NaCl), and the conductance distribution of the PaMscS2 angstrom pore is 34.9 ± 7.0 pA (mean ± SD, from 18 independent insertion events) ( Figure 1 D) The ion transport results of PaMscS1 showed that PaMscS1 has better selectivity for Br- ( Figure 6 ).
[0137] Taking the detection of single nucleotides as an example, when the PaMscS1 angstrom hole is inserted into the BLM and dNTPs are present in the -cis end, the translocation signal of dNTPs can be observed under positive voltage. The translocation frequency of dNTPs increases with the increase of voltage ( Figure 7 Both PaMscS1 and PaMscS2 were analyzed for dNTP mixture detection (dNTPs concentration: 0.2mM, voltage: +50mV, -cis end: 300mM NaCl, -trans end: 30mM NaCl). Obvious differences in the distribution of blocking currents can be observed between the two mutants, indicating that the translocation of dNTPs is associated with the side pores of the PaMscS angstrom ( Figure 1 E). That is, under the same detection conditions, the distribution of the blocking current of dNTPs for PaMscS1 and PaMscS2 angstrom pores is different. Specifically, the blocking rate of the PaMscS1 angstrom pore for the four dNTPs mixtures shows three peaks, while the blocking rate of the PaMscS2 angstrom pore for the four dNTPs mixtures shows two peaks. Because the difference between the PaMscS1 and PaMscS2 mutations lies in the difference in the amino acids of the side pores, it is speculated that the detection signal of dNTPs is related to the side pores. Since PaMscS1 has a better discrimination effect on dNTP mixtures, it is used to distinguish single nucleotide mixtures. As for PaMscS2, it exhibits a more stable channel conductance and a relatively higher membrane fusion efficiency, so it is more suitable for rapid diagnosis ( Figure 4 AC). The wild-type PaMscS angstrom pore showed two peaks in blocking rate for the four dNTPs mixtures ( Fig.14 ). The current trajectory and residence time distribution of PaMscS1 detecting single nucleotides are shown in Figure 2. Fig.12 shown.
[0138] Compared with the reported α-hemolysin containing am7βCD, MoS2 and α-Hederin, although the detection accuracy of the PaMscS1 angstrom pore is lower than that of the best reported biological nanopore containing am7βCD conjugate (i.e., constructed using α-hemolysin mutant protein and 6-amino-6-deoxy-β-cyclodextrin aptamer), the translocation speed is comparable to that of solid-state nanopores. In the (ssDNA) detection experiment, 50 μM ssDNA was detected under the buffer conditions of 30 mM NaCl / 300 mM NaCl and a bias voltage of +50 mV, and no translocation events were observed due to its narrow channel size ( Figure 8 ). Therefore, the PaMscS variant angstrom pore has the potential to be a useful small molecule sensor.
[0139] Embodiment 3
[0140] Selective tuning of the PaMscS1 angstrom pore for optimized dNTPs detection:
[0141] Considering the mechanical sensitivity of PaMscS1 angstrom pore, the selectivity of PaMscS1 angstrom pore was adjusted by applying different osmotic pressure differences. In order to maintain the constant charge characteristics of dCTP and dGTP under different osmotic pressure differences, the concentration of the conductivity buffer at the -cis end was kept at 300mM and the concentration of the conductivity buffer at the -trans end was changed to change the osmotic pressure difference. The detection ability of PaMscS1 angstrom pore for large dGTP and small dCTP was tested under three osmotic pressure difference conditions, including symmetric conditions ( Fig.10 A, 300 mM NaCl / 300 mM NaCl, +50 mV bias voltage), low osmotic pressure difference condition ( Fig.10 B, 100 mM NaCl / 300 mM NaCl, +50 mV bias voltage) and high osmotic pressure difference conditions ( Fig.10 C, 30 mM NaCl / 300 mM NaCl, +50 mV bias voltage). Under symmetric osmotic pressure conditions, the translocation frequency of dCTP increased from 0.16 ± 0.03 s -1 Increased to 0.22±0.07s -1 , while dGTP from 0.09±0.02s -1 Change to 0.07±0.003s -1 Under low osmotic pressure difference (LOD) conditions, the translocation frequency of dCTP increased from 0.34 ± 0.1 s -1 Increased to 0.67±0.14s -1 , while dGTP from 0.06±0.01s -1 Increase to 0.3±0.04s -1Under high osmotic pressure difference (HOD) conditions, the translocation frequency of dCTP increased from 0.12 ± 0.04 s -1 Increased to 0.22±0.07s -1 , while dGTP from 0.37±0.08s -1 Increased to 1.12±0.12s -1 ( Fig.10 D, n = 3 per experiment, mean ± SEM). Fig.10 E summarizes the detection of dGTP and dCTP, and it is concluded that the low osmotic pressure difference condition shows the highest increase in translocation events for dCTP, while the high osmotic pressure difference condition shows the highest increase in translocation events for dGTP ( Fig.10 E). Low osmotic pressure difference conditions show balanced capture capacity for both dCTP and dGTP compared to the reduced capture efficiency of dCTP under high osmotic pressure conditions. Given that the size and charge properties of dGTP and dCTP remain constant under given experimental conditions, and that the channel size of the MscS family can vary under different pressure, osmotic pressure conditions, or membrane potentials, the experimenters can conclude that the differences in selectivity of the PaMscS1 angstrom pore for dNTPs are caused by changes in channel size under different osmotic pressure difference conditions.
[0142] Embodiment 4
[0143] Detection of SARS-CoV-2 in clinical samples by PaMscS2
[0144] Rapid and simple nucleic acid detection of SARS-CoV-2 is an important preventive method for the spread of SARS-CoV-2. In this example, the experimenter used specific primers of SARS-CoV-2 Orf1ab (cDNA) to detect SARS-CoV-2 ( Figure 2 A), the purpose of which is to verify the rapid diagnostic ability of the angstrom pore involved in the present invention for known nucleic acids. Since the PaMscS2 angstrom pore has a high membrane fusion efficiency, it was used in this experiment. The target sequence is 172bp, and fragment analysis of the amplified product shows that the primers can be used for amplification of the target gene (Table 1). The SARS-CoV-2Orf1ab gene was synthesized and the gradient concentration of the SARS-CoV-2Orf1ab gene was detected. In the concentration range of 10^3 copies / mL to 10^11 copies / mL, the synthesized SARS-CoV-2Orf1ab gene can be detected ( Figure 2B). Then, 22 clinical samples were tested, including 15 samples from confirmed patients and 7 samples from healthy controls. The 15 positive samples and 6 negative samples (patient numbers: 1-15, 17-22) tested by Empiric pore all showed results consistent with clinical tests (Table 2), and 1 negative sample was diagnosed as a false positive result (patient number: 16). The specificity of this method was 86% and the sensitivity was 100% ( Figure 2 C). As a nanodevice for nucleic acid amplification monitoring, the PaMscS mutant angstrom pore can be combined with various NAATs such as polymerase chain reaction and chain displacement amplification ( Fig. 9 ) to detect target genes ( Figure 2 D). The principle is that specific primers can trigger the amplification of target nucleic acids, and the amplification process will lead to a decrease in the content of dNTPs in the system, which will be detected by the angstrom pore, indicating the presence of target nucleic acids in the system. The angstrom pore also has the potential to monitor the reverse transcription process, which can achieve rapid and amplification-free detection of target RNA.
[0145] Table 1 Fragment length and amplification product concentration
[0146] Table 2 Ct values and angstrom pore detection results of clinical samples
[0147] Embodiment five:
[0148] Detection of multiple biomarkers through PaMscS1 angstrom pores:
[0149] The researchers designed a dNTP barcode probe differentiation strategy and verified its application in the detection of multiple biomarkers through the PaMscS1 angstrom pore. Two probes were designed to bind to the target DNA sequence and cause specific dNTPs consumption in the chain polymerization reaction, including the miR21 probe (probe A): including a sequence complementary to miR21 and a polyT barcode sequence; the AFP aptamer probe (probe B): including a sequence complementary to the AFP aptamer and a poly C barcode sequence (see Table 3 for the sequence information of miR21 and AFP aptamers). When probe A or probe B is present in the sample, the polymerase chain reaction can be activated to consume dATP or dGTP in the reaction system ( Fig.11 A).
[0150] The control sample without target sequence, the sample with miR21, the sample with AFP aptamer and the sample with both miR21 and AFP aptamer were tested. The corresponding current traces and blockade current distributions are shown in Fig.11 B and 11C. It can be observed that in the control group (samples without miR21 and AFP aptamer), dATP (δf dATP =f dATP / f 背景 The relative increase in the frequency of translocation events of dGTP (δf dGTP =f dGTP / f 背景 ) had a relative increase in the frequency of translocation events of 1.8 ± 0.03. In samples with miR21, δf dATP was significantly lower than that of the control group (1.4±0.1, mean±SEM). dGTP decreased to 1.0±0.3 (mean±SEM). For samples with both miR21 and AFP aptamer, δf dATP (1.1±0.2, mean±SEM) and δf dGTP (1.3±0.2, mean±SEM) were decreased ( Fig.11 D) These results indicate that PaMscS1 can detect single or multiple biomarkers simultaneously (n ≥ 3 per experiment).
[0151] Table 3 Sequences of miR21 and AFP aptamers
[0152] Embodiment six:
[0153] A strategy to enhance the signal:
[0154] A. Enhance the detection limit of the object to be detected by ion regulation, specifically for dNTPs, by adding divalent cations such as nickel ions and cobalt ions to the cytoplasmic end of the angstrom pore involved in the present invention, the detection limit of dNTPs can be improved; B. Enhance the signal-to-noise ratio by regulating the osmotic difference of the conductive liquid, specifically by increasing the concentration of the conductive liquid, the ability to distinguish drug molecules with similar structures can be improved, and by increasing the osmotic difference of the conductive liquid on both sides of the phospholipid membrane, the detection effect of dGTP can be improved.
[0155] Embodiment seven:
[0156] Electrophysiological detection based on EcMscS angstrom pore
[0157] When wild-type EcMscS channels were embedded in a bilayer lipid membrane (BLM), a stable channel current jump was observed at a voltage of +100 mV ( Fig.15 ). The wild-type EcMscS channel current remained stable at voltages ranging from -100 mV to +100 mV ( Fig.16 The conductance of the wild-type EcMscS angstrom pore is 0.334±0.028nS (-cis end: 300mM NaCl, -trans end: 30mM NaCl)( Fig.17 ). Fig.18 ac show the structures of EcMscS, TtMscS and HpMscS, respectively, which are highly similar to the structure of PaMscS, that is, they are all radially symmetrical and cylindrically shaped heptamer structures. Fig.18 ac and Fig.18 d The sequences of PaMscS were further compared with those of EcMscS, TtMscS, and HpMscS (sequence information is shown in Table 4). The results showed that EcMscS, TtMscS, HpMscS and PaMscS have certain homology, but this homology is not highly homologous. The similarity between EcMscS and PaMscS is only 60%, but both of them have the ability to detect analytes. Therefore, those skilled in the art can understand that the key to determining that bacterial MscS can be used as an angstrom pore to detect analytes lies in its radially symmetrical and cylindrical heptamer structure and channel pore size, not just homology.
[0158] The embodiments of the present invention are described above in conjunction with the accompanying drawings, but the present invention is not limited to the above-mentioned specific implementation modes, which are merely illustrative rather than restrictive. Under the guidance of the present invention, ordinary technicians in this field can also make many forms without departing from the scope of protection of the present invention and the claims, all of which are within the protection of the present invention.
[0159] References 1. Liu, H. & Johnston, APRA Programmable Sensor to Probe the Internalization of Proteins and Nanoparticles in Live Cells. Angewandte Chemie International Edition 52, 5744–5748 (2013). 2.Li,X.etal.PlantDNAbarcoding:from geneto genome.BiologicalReviews90,157–166(2015). 3.Wilson,P.M.etal.Anovel fluorescence-basedassayfortherapiddetectionandquantificationofcellulardeoxyribonucleosidetriphosphates.NucleicAcidsResearch39,e112–e112(2011). 4.Fuller,C.W.etal.Real-time single-molecule electronic DNAsequencingby synthesisusingpolymer-taggednucleotides onananoporearray.Proceedings oftheNationalAcademyofSciences ofthe UnitedStatesofAmerica113,5233–5238(2016). 5.Butler,T.Z.,Pavlenok,M.,Derrington,I.M.,Niederweis,M.&Gundlach,J.H.Single-moleculeDNAdetectionwith anengineeredMspAproteinnanopore.Proceedings oftheNationalAcademyofSciences105,20647–20652(2008). 6.Goyal,P.etal.Structural andmechanistic insights intothebacterialamyloid secretionchannel CsgG.Nature516,250–253(2014). 7.Cao,C.etal.Mapping the sensing spots ofaerolysinfor singleoligonucleotides analysis.NatureCommunications9,2823(2018). 8.Wendell,D.etal.Translocation ofdouble-strandedDNAthroughmembrane-adaptedphi29motorproteinnanopores.NatureNanotechnology4,765–772(2009). 9.Manrao,E.A.etal.ReadingDNAat single-nucleotideresolutionwithamutantMspAnanoporeandphi29 DNApolymerase.NatureBiotechnology30,349–353(2012). 10.Bowden,R.etal.Sequencing ofhumangenomeswithnanoporetechnology.Nature Communications10,1869(2019). 11.Wang,Y.,Zheng,D.,Tan,Q.,Wang,M.X.&Gu,L.-Q.Nanopore-baseddetectionofcirculating microRNAs inlung cancerpatients.NatureNanotechnology6,668–674(2011). 12.Thakur,A.K.&Movileanu,L.Real-time measurementofprotein–proteininteractions atsingle-moleculeresolutionusing abiologicalnanopore.NatureBiotechnology37,96–104(2019). 13.Astier,Y.,Braha,O.&Bayley,H.Toward singlemoleculeDNA sequencing:Directidentificationofribonucleoside anddeoxyribonucleoside 5′-monophosphatesbyusing anengineeredproteinnanoporeequippedwith amolecularadapter.JournaloftheAmerican ChemicalSociety128,1705–1710(2006). 14.Clarke,J.etal.Continuousbase identification for single-moleculenanoporeDNA sequencing.Naturenanotechnology4,265–70(2009). 15.Jeong,K.-B.etal.Alpha-HederinNanoporefor SingleNucleotideDiscrimination.ACSNano13,1719–1727(2019). 16.Venta,K.etal.Differentiation ofShort,Single-StrandedDNAHomopolymers in Solid-StateNanopores.ACSNano7,4629–4636(2013). 17.Garaj,S.etal.Graphene as a subnanometretrans-electrodemembrane.Nature467,190–193(2010). 18.Booth,I.R.&Blount,P.TheMscS andMscLFamilies ofMechanosensitive ChannelsActasMicrobialEmergencyReleaseValves.JournalofBacteriology194,4802–4809(2012). 19.Akitake,B.,Anishkin,A.&Sukharev,S.The“Dashpot”Mechanism ofStretch-dependentGating inMscS.TheJournal ofGeneralPhysiology125,143–154(2005). 20.Bass,R.B.Crystal Structure ofEscherichia coli MscS,a Voltage-Modulated and Mechanosensitive Channel.Science298,1582–1587(2002). 21.Lee,J.-Y.,Na,I.Y.,Park,Y.K.&Ko,K.S.Genomic variations betweencolistin-susceptible and-resistantPseudomonas aeruginosa clinical isolatesand their effects on colistin resistance.JournalofAntimicrobialChemotherapy69,1248–1256(2014). 22.Machiyama,H.,Tatsumi,H.&Sokabe,M.Structural changes in thecytoplasmic domain ofthe mechanosensitivechannel MscS duringopening.Biophysicaljournal97,1048–57(2009). 23.Feng,J.et al.Identification ofsingle nucleotides in MoS2nanopores.Nature Nanotechnology10,1070–1076(2015). 24.Gamini,R.,Sotomayor,M.,Chipot,C.&Schulten,K.Cytoplasmic DomainFilter Function in theMechanosensitive Channel ofSmall Conductance.BiophysicalJournal101,80–89(2011). 25.Perozo,E.&Rees,D.C.Structure and mechanism in prokaryoticmechanosensitive channels.Current Opinion inStructuralBiology13,432–442(2003). 26.Maksaev,G.&Haswell,E.S.MscS-Like10 is a stretch-activated ionchannel from Arabidopsis thaliana with apreference for anions.Proceedingsofthe NationalAcademy ofSciences109,19015–19020(2012). 27.Rozevsky,Y.et al.Quantification ofmRNA Expression Using Single-Molecule Nanopore Sensing.ACSnanoacsnano.0c06375(2020).doi:10.1021 / acsnano.0c06375 28.Ouldali,H.et al.Electrical recognition ofthe twentyproteinogenicamino acids using an aerolysin nanopore.Nature biotechnology38,176–181(2020). 29.LEI,J.&FRANK,J.Automated acquisition ofcryo-electron micrographsfor single particle reconstruction on anFEI Tecnai electronmicroscope.Journal ofStructuralBiology150,69–80(2005). 30.Zheng,S.Q.et al.MotionCor2:anisotropic correction ofbeam-inducedmotion for improved cryo-electronmicroscopy.Nature Methods14,331–332(2017). 31.Punjani,A.,Rubinstein,J.L.,Fleet,D.J.&Brubaker,M.A.cryoSPARC:algorithms for rapid unsupervisedcryo-EM structure determination.NatureMethods14,290–296(2017). 32.Punjani,A.,Zhang,H.&Fleet,D.J.Non-uniform refinement:Adaptiveregularization improves single particlecryo-EM reconstruction.bioRxiv2019.12.15.877092(2019).doi:10.1101 / 2019.12.15.877092 33.Wang,W.etal.The Structure ofan Open Form ofan E.coliMechanosensitive Channel at 3.45 A Resolution.Science321,1179–1183(2008). 34.Jurcik,A.et al.CAVER Analyst 2.0:analysis and visualizationofchannels and tunnels in protein structures andmolecular dynamicstrajectories.Bioinformatics(Oxford,England)34,3586–3588(2018). 35.Smart,O.S.,Goodfellow,J.M.&Wallace,B.A.The pore dimensionsofgramicidin A.Biophysicaljournal65,2455–60(1993). 36.Kefauver,J.M.,Ward,A.B.&Patapoutian,A.Discoveries in structure andphysiology ofmechanically activatedion channels.Nature 587,567–576(2020). 37.Hurst AC,Petrov E,Kloda A,Nguyen T,Hool L,Martinac B.MscS,thebacterial mechanosensitive channel ofsmall conductance.Int J Biochem CellBiol.2008;40(4):581-585. 38.Malcolm,H.R.and Maurer,J.A.(2012),The Mechanosensitive ChannelofSmall Conductance(MscS) Superfamily:Not Just Mechanosensitive Channels Anymore.ChemBioChem,13:2037-2043.
Claims
1. A method for detecting the presence of a target nucleic acid in a sample, characterized in that: The steps include: S1: placing the sample in a nucleic acid amplification system and performing nucleic acid amplification, determining the number of substrate nucleotides in the nucleic acid amplification system, and obtaining a nucleic acid amplification product of the sample; S2: adding the nucleic acid amplification product of the sample to a single-channel electrophysiological detection system, wherein the single-channel electrophysiological detection system comprises: a transmembrane pore, an insulating membrane, a first medium, and a second medium, wherein the transmembrane pore is embedded in the insulating membrane, the insulating membrane separates the first medium from the second medium, the transmembrane pore provides a channel connecting the first medium and the second medium, and the nucleic acid amplification product of the sample is added to the first medium; S3 applies a driving force between the first medium and the second medium, so that the remaining nucleotides in the nucleic acid amplification product of the sample interact with the transmembrane pore and generate an electrical signal; S4 quantifies the electrical signal to obtain the number of the remaining nucleotides; S5 compares the number of the remaining nucleotides with the number of the substrate nucleotides to determine whether the target nucleic acid exists in the sample.
2. The method according to claim 1, characterized in that The transmembrane pore is a MscS variant angstrom pore, and the MscS variant optionally includes a side pore volume variant and / or a side pore charge variant.
3. The method according to claim 2, characterized in that The charge properties and / or pore size of the opening of the MscS variant angstrom pore are adjustable; the method for adjusting the opening optionally includes subjecting the insulating membrane to mechanical force stimulation and / or changing the physical state of the insulating membrane, and the mechanical force stimulation optionally includes one or more of the change in the osmotic pressure difference of the medium on both sides of the insulating membrane, the direct physical stimulation of the insulating membrane by microneedles, and the stimulation of the insulating membrane by negative air pressure.
4. The method according to claim 3, characterized in that The aperture of the opening can be adjusted in the following ways: (1) Selection of the types of the first medium and the second medium; and / or (2) The osmotic pressure difference between the first medium and the second medium.
5. The method according to claim 4, characterized in that The osmotic pressure difference between the first medium and the second medium is adjusted by the concentration difference between the first medium and the second medium, and the concentration difference between the first medium and the second medium is optionally about 0-270 mM.
6. The method according to claim 2, characterized in that The MscS variant angstrom is derived from bacilli, optionally including one or more of Pseudomonas aeruginosa, Escherichia coli, Thermoanaerobacterium Tengchongensis and Helicobacter pylori.
7. The method according to claim 2, characterized in that The MscS variant Angstrom pore is a PaMscS variant Angstrom pore, optionally including one or more of the following variants: 130A, 130H, 180R, 271I, 130S and 130P.
8. The method according to claim 1, characterized in that The nucleotides include ribonucleotides and / or deoxyribonucleotides, and the nucleotides may optionally include one or more of dGTP, dATP, dTTP, dCTP, dUTP, GTP, ATP, TTP, CTP, and UTP.
9. The method according to any one of claims 1 to 8, characterized in that The nucleic acid amplification system further comprises: (1) a probe, wherein the probe comprises a complementary region and a repeat region, wherein the complementary region comprises a sequence complementary to the target nucleic acid, and the repeat region comprises an oligonucleotide sequence repeating the same base, wherein the base comprises A, T, C, G, or U; or (2) Primers specific for the target nucleic acid.
10. The method according to claim 1, characterized in that The target nucleic acid is a coronavirus nucleic acid, and the coronavirus may optionally include one or more of SARS-CoV-2, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV and MERS-CoV.
11. A virus rapid detection kit, comprising: (1) an MscS angstrom pore, wherein the MscS angstrom pore optionally comprises a side pore volume variant and / or a side pore charge variant of MscS; (2) an insulating membrane, optionally comprising a phospholipid membrane and / or a polymer membrane; (3) an electroconductive liquid, wherein the electroconductive liquid optionally includes one or more of a sodium chloride solution, a lithium chloride solution, a cesium chloride solution, a potassium chloride solution, and a sodium bromide solution; (4) Primers or probes specific for the nucleic acid of the virus.
12. The kit according to claim 11, characterized in that The angstrom pore is a PaMscS variant angstrom pore, optionally including one or more of 130A, 130H, 180R, 271I, 130S and 130P.
